Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis

Abstract

Background

This systematic review and meta-analysis aimed to assess the prognostic value of sequential of abiraterone (ABI) and enzalutamide (ENZ) therapy in patients with castration-resistant prostate cancer (CRPC).

Methods

PUBMED, Web of Science, Cochrane Library, and Scopus databases were searched for articles published prior to December 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deemed eligible if they compared overall survival (OS), combined progression-free survival (PFS), combined prostate specific antigen (PSA)-PFS, and PSA response rates in CRPC patients receiving sequential ABI/ENZ or vice versa. PSA response to both the first and second agents was defined as a >50% decrease in PSA achieved with each of these agents. Formal meta-analyses were performed for these outcomes.

Results

Ten studies with 1096 patients were eligible for the systematic review and eight studies with 643 patients for the meta-analysis. The ABI-to-ENZ sequence was significantly associated with better PFS (pooled hazard ratio (HR): 0.62, 95% confidential interval (CI): 0.49–0.78, P < 0.001), and PSA–PFS (pooled HR: 0.48, 95% CI: 0.38–0.61, P < 0.001) than the ENZ-to-ABI sequence. PSA response rates of both agents were significantly better with the ABI-to-ENZ sequence (risk ratio: 0.21, 95% CI: 0.09–0.47, P < 0.001). In contrast, treatment sequence was not significantly associated with OS (pooled HR: 0.77, 95% CI: 0.59–1.01, P = 0.055).

Conclusions

ABI-to-ENZ sequential therapy in patients with CRPC was associated with better PFS, PSA–PFS, and PSA response rates. Regardless of sequencing, response to drug therapy was transient for both ABI and ENZ when either agent was used as a secondary therapy. Despite this, treatment sequencing is important to achieve the maximum possible benefit from available drugs in CRPC.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Study selection process.
Fig. 2: Forest plot (association of androgen receptor axis-targeted (ARAT) treatment sequence with oncological outcomes).
Fig. 3: Forest plot (association of androgen receptor axis-targeted (ARAT) treatment sequence with PSA response rate).

References

  1. 1.

    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer J clinicians. 2018;68:7–30.

    Google Scholar 

  2. 2.

    Kluth LA, Shariat SF, Kratzik C, Tagawa S, Sonpavde G, Rieken M, et al. The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. World J Urol. 2014;32:669–76.

    CAS  Article  Google Scholar 

  3. 3.

    de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

    Article  Google Scholar 

  4. 4.

    Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–48.

    CAS  Article  Google Scholar 

  5. 5.

    Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.

    CAS  Article  Google Scholar 

  6. 6.

    Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.

    Article  Google Scholar 

  7. 7.

    Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, et al. Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting. Urol Oncol. 2018;36:500.e501–500.e509.

    Article  Google Scholar 

  8. 8.

    Chi K, Hotte SJ, Joshua AM, North S, Wyatt AW, Collins LL, et al. Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. Ann Oncol: Off J Eur Soc Med Oncol. 2015;26:2044–56.

    CAS  Article  Google Scholar 

  9. 9.

    Maughan BL, Luber B, Nadal R, Antonarakis ES. Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study. Prostate. 2017;77:33–40.

    CAS  Article  Google Scholar 

  10. 10.

    Mori K, Kimura T, Onuma H, Kimura S, Yamamoto T, Sasaki H, et al. Lactate dehydrogenase predicts combined progression-free survival after sequential therapy with abiraterone and enzalutamide for patients with castration-resistant prostate cancer. Prostate. 2017;77:1144–50.

    CAS  Article  Google Scholar 

  11. 11.

    Miyake H, Hara T, Tamura K, Sugiyama T, Furuse H, Ozono S, et al. Comparative assessment of efficacies between 2 alternative therapeutic sequences with novel androgen receptor-axis-targeted agents in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer. Clin Genitourin cancer. 2017;15:e591–7.

    Article  Google Scholar 

  12. 12.

    Terada N, Maughan BL, Akamatsu S, Kobayashi T, Yamasaki T, Inoue T, et al. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: the Kyoto-Baltimore collaboration. Int J Urol: Off J Jpn Urological Assoc. 2017;24:441–8.

    CAS  Article  Google Scholar 

  13. 13.

    Matsubara N, Yamada Y, Tabata K, Satoh T, Kamiya N, Suzuki H, et al. Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2018;16:142–8.

    Article  Google Scholar 

  14. 14.

    Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 2018;8:444–57.

    CAS  Article  Google Scholar 

  15. 15.

    Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019;20:1730–9.

    CAS  Article  Google Scholar 

  16. 16.

    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.

    Article  Google Scholar 

  17. 17.

    Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.

    Article  Google Scholar 

  18. 18.

    Deeks JJ, Dinnes J, D’Amico R, Sowden AJ, Sakarovitch C, Song F, et al. Evaluating non-randomised intervention studies. Health Technol Assess. 2003;7:1–173.

    Article  Google Scholar 

  19. 19.

    Altman DG, Bland JM. How to obtain the confidence interval from a P value. BMJ (Clin Res ed). 2011;343:d2090.

    Article  Google Scholar 

  20. 20.

    Altman DG, Bland JM. How to obtain the P value from a confidence interval. BMJ (Clin Res ed). 2011;343:d2304.

    Article  Google Scholar 

  21. 21.

    DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin trials. 2007;28:105–14.

    Article  Google Scholar 

  22. 22.

    DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin trials. 1986;7:177–88.

    CAS  Article  Google Scholar 

  23. 23.

    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clin Res ed). 2003;327:557–60.

    Article  Google Scholar 

  24. 24.

    Sterne JAC, Harbord RM. Funnel plots in meta-analysis. Stata J. 2004;4:127–41.

    Article  Google Scholar 

  25. 25.

    Miyamae K, Kitani K, Hara K, Nakakuma K, Hamada S, Hamada Y. Clinical study of sequential therapy with abiraterone and enzalutamide following docetaxel therapy for castration-resistant prostate cancer. Jpn J Urol. 2018;108:74–79.

    Article  Google Scholar 

  26. 26.

    Komura K, Fujiwara Y, Uchimoto T, Saito K, Tanda N, Matsunaga T, et al. Comparison of radiographic progression-free survival and PSA response on sequential treatment using abiraterone and enzalutamide for newly diagnosed castration-resistant prostate cancer: a propensity score matched analysis from multicenter cohort. J Clin Med. 2019;8.

  27. 27.

    Kobayashi T, Terada N, Kimura T, Matsubara N, Murakami K, Mori K, et al. Sequential use of androgen receptor axis-targeted agents in chemotherapy-naive castration-resistant prostate cancer: a multicenter retrospective analysis with 3-Year follow-up. Clin Genitourin Cancer. 2020;18:e46–54.

    Article  Google Scholar 

  28. 28.

    Okita K, Hatakeyama S, Narita S, Takahashi M, Sakurai T, Kawamura S, et al. The effect of treatment sequence on overall survival for men with metastatic castration-resistant prostate cancer: a multicenter retrospective study. Clin Genitourin Cancer. 2019. [Epub ahead of print].

  29. 29.

    Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30:637–43.

    CAS  Article  Google Scholar 

  30. 30.

    Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol. 2015;67:53–60.

    CAS  Article  Google Scholar 

  31. 31.

    de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wulfing C, et al. Cabazitaxel versus Abiraterone or Enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381:2506–18.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

Project development: KM, TK, SE, AB, PIK, and SFS. Data collection: KM and NM. Data analysis: KM and NM. Manuscript writing/editing: KM, NM, HM, FQ, RSM, BP, SK, TK, SE, AB, PIK, and SFS.

Corresponding author

Correspondence to Shahrokh F. Shariat.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mori, K., Miura, N., Mostafaei, H. et al. Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis (2020). https://doi.org/10.1038/s41391-020-0222-6

Download citation

Further reading